US 12,357,671 B2
Compositions and methods for invasive and non-invasive procedural skincare
John A. Garruto, Carlsbad, CA (US); and Alan David Widgerow, Carlsbad, CA (US)
Assigned to Alastin Skincare, Inc., Carlsbad, CA (US)
Filed by Alastin Skincare, Inc., Carlsbad, CA (US)
Filed on Aug. 29, 2022, as Appl. No. 17/898,223.
Application 17/898,223 is a continuation of application No. 17/192,494, filed on Mar. 4, 2021, granted, now 11,426,443.
Application 17/192,494 is a continuation of application No. 16/870,643, filed on May 8, 2020, granted, now 11,426,442.
Application 16/870,643 is a continuation of application No. 16/293,467, filed on Mar. 5, 2019, granted, now 10,688,147, issued on Jun. 23, 2020.
Application 16/293,467 is a continuation of application No. 16/004,259, filed on Jun. 8, 2018, granted, now 10,286,030, issued on May 4, 2019.
Application 16/004,259 is a continuation of application No. 15/423,530, filed on Feb. 2, 2017, granted, now 10,086,035, issued on Oct. 2, 2018.
Claims priority of provisional application 62/303,332, filed on Mar. 3, 2016.
Claims priority of provisional application 62/291,376, filed on Feb. 4, 2016.
Prior Publication US 2024/0016880 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61K 8/26 (2006.01); A61K 8/37 (2006.01); A61K 8/41 (2006.01); A61K 8/42 (2006.01); A61K 8/49 (2006.01); A61K 8/55 (2006.01); A61K 8/58 (2006.01); A61K 8/60 (2006.01); A61K 8/64 (2006.01); A61K 8/891 (2006.01); A61K 8/894 (2006.01); A61K 8/97 (2017.01); A61K 9/00 (2006.01); A61K 31/01 (2006.01); A61K 31/047 (2006.01); A61K 31/16 (2006.01); A61K 31/231 (2006.01); A61K 31/353 (2006.01); A61K 31/47 (2006.01); A61K 31/685 (2006.01); A61K 31/695 (2006.01); A61K 31/7048 (2006.01); A61K 31/74 (2006.01); A61K 36/05 (2006.01); A61K 36/28 (2006.01); A61K 38/06 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); A61K 47/34 (2017.01); A61Q 19/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 38/08 (2013.01) [A61K 8/26 (2013.01); A61K 8/37 (2013.01); A61K 8/416 (2013.01); A61K 8/42 (2013.01); A61K 8/4973 (2013.01); A61K 8/498 (2013.01); A61K 8/553 (2013.01); A61K 8/585 (2013.01); A61K 8/602 (2013.01); A61K 8/64 (2013.01); A61K 8/891 (2013.01); A61K 8/894 (2013.01); A61K 8/97 (2013.01); A61K 9/0014 (2013.01); A61K 31/01 (2013.01); A61K 31/047 (2013.01); A61K 31/16 (2013.01); A61K 31/231 (2013.01); A61K 31/353 (2013.01); A61K 31/47 (2013.01); A61K 31/685 (2013.01); A61K 31/695 (2013.01); A61K 31/7048 (2013.01); A61K 31/74 (2013.01); A61K 36/05 (2013.01); A61K 36/28 (2013.01); A61K 38/06 (2013.01); A61K 47/14 (2013.01); A61K 47/186 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 47/34 (2013.01); A61Q 19/00 (2013.01); A61Q 19/08 (2013.01); A61K 2300/00 (2013.01); A61K 2800/5922 (2013.01); A61K 2800/594 (2013.01); A61K 2800/75 (2013.01); A61K 2800/884 (2013.01)] 20 Claims
 
1. A topical composition, comprising:
a tripeptide-1 present at 0.5-50 ppm; and
a hexapeptide-12 present at 0.5-50 ppm,
wherein the tripeptide-1 and hexapeptide-12 synergistically promote skin repair or wound healing.